| CGNH Stock | | | USD 0.0001 0.00 0.00% |
CEO
Dr. Yahia Gawad, MB, Ch.B., MD, MSc., is the Chief Executive Officer, Director of CardioGenics Holdings Inc. Dr. Gawad is a PhysicianScientist with primary training in Cardiology, Biochemistry and Immunology. He received his medical education and postgraduate training at the University of Alexandria and the University of Toronto. Dr. Gawad academic and commercial experience and include many years of designing and managing cardiovascular disease research and product development. Dr. Gawad was a cofounder of a division of Nanogen where he held the position of VicePresident, Medical Affairs. Prior to that, he was Director of Clinical Research and Development at Spectral Diagnostics Inc. . For the past 17 years, he was working on cardiac diagnostic test products. He has prepared, submitted and obtained FDA regulatory approvals for several cardiac test products currently being marketed . since 2009.
| Age | 65 |
| Tenure | 16 years |
| Phone | 905-673-8501 |
| Web | https://www.cardiogenics.com |
CardioGenics Holdings Management Efficiency
The company has return on total asset
(ROA) of
(1.155) % which means that it has lost $1.155 on every $100 spent on assets. This is way below average. CardioGenics Holdings' management efficiency ratios could be used to measure how well CardioGenics Holdings manages its routine affairs as well as how well it operates its assets and liabilities.
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. The company was founded in 1997 and is headquartered in Mississauga, Canada. Cardiogenics Holdings operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 4 people. CardioGenics Holdings [CGNH] is a
Pink Sheet which is traded between brokers over the counter.
Management Performance
CardioGenics Holdings Management Team
Elected by the shareholders, the CardioGenics Holdings' board of directors comprises two types of representatives: CardioGenics Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CardioGenics. The board's role is to monitor CardioGenics Holdings' management team and ensure that shareholders' interests are well served. CardioGenics Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CardioGenics Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
CardioGenics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CardioGenics Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in CardioGenics Pink Sheet
CardioGenics Holdings financial ratios help investors to determine whether CardioGenics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CardioGenics with respect to the benefits of owning CardioGenics Holdings security.